←back to thread

372 points Eumenes | 1 comments | | HN request time: 0.259s | source
1. oksurewhynot ◴[] No.42199869[source]
I thought this was known about older GLP-1 antagonists like semaglutide, which is why there's some excitement around the newer dual-action types like tirzepatide? My understanding is the newer drugs cause substantially less muscle mass loss.